RESEARCH ARTICLE


Anti-Vascular Endothelial Growth Factor Therapy as an Adjunct to Diabetic Vitrectomy



Mushfig Karimov1, Lala Akhundova1, *
iD

1 Department of Diabetic Eye Diseases, Zarifa Aliyeva National Ophthalmology Centre, Baku, Azerbaijan


Article Metrics

CrossRef Citations:
1
Total Statistics:

Full-Text HTML Views: 1691
Abstract HTML Views: 641
PDF Downloads: 512
Total Views/Downloads: 2844
Unique Statistics:

Full-Text HTML Views: 750
Abstract HTML Views: 340
PDF Downloads: 361
Total Views/Downloads: 1451



Creative Commons License
© 2021 Karimov and Akhundova.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Address correspondence to this author at the Department of Diabetic Eye Diseases, Zarifa Aliyeva National Ophthalmology Centre, 32/15 Javadkhan str., Baku, Azerbaijan; Tel: +994503565181; E-mail: akhundova.lale@gmail.com


Abstract

Introduction:

The purpose of this work is to study the efficacy of the preoperative intravitreal administration of bevacizumab as an adjunct to vitrectomy in patients with Proliferative Diabetic Retinopathy (PDR).

Methods:

This retrospective comparative study was performed on 118 eyes (118 patients) with proliferative diabetic retinopathy (PDR), which underwent vitrectomy surgery at the Department of Diabetic Eye Disease at Zarifa Aliyeva National Ophthalmology Centre (Baku, Azerbaijan) in 2015-2019. The main group (the bevacizumab group) included 48 eyes with PDR that received intravitreal administration of bevacizumab (Avastin; Genentech Inc., USA) within one week before vitrectomy; the control group included 70 eyes that did not receive a bevacizumab injection for at least 3 months before the vitrectomy. The minimum follow-up was 12 months.

Results:

In both groups, complete retinal attachment after primary vitrectomy was achieved in all eyes (100%). Clinically significant intraoperative haemorrhage was observed in the preoperative bevacizumab injection group in 31.2% and the control group- 51.4%, p = 0.030. The preoperative bevacizumab injection reduced the risk of clinically significant haemorrhage by 2.3 times and the need for endodiathermy by 2.7 times (p = 0.031 and p = 0.024, respectively). Early vitreous cavity haemorrhage was observed in 15.0% in the bevacizumab group and in 35.5% in the control group (p = 0.038). The preoperative injection of bevacizumab before vitrectomy reduced the risk of vitreous cavity haemorrhage in the early postoperative period by 3.0 times (p = 0.036).

Conclusion:

The preoperative use of bevacizumab as an adjunct to diabetic vitrectomy can help reduce the incidence of intraoperative and early postoperative vitreous cavity haemorrhage, which leads to better functional results in the early postoperative period. Over the long-term follow-up period, the effect of the preoperative bevacizumab injections decreases.

Keywords: Proliferative diabetic retinopathy, Vitrectomy, Endodiathermy, Vitreous cavity haemorrhage, Anti-VEGF therapy, Intravitreal bevacizumab.